CTLA-4 is one of a small number of immune genes whose deletion triggers fatal lymphoproliferative disease. Its importance in immune regulation is unquestioned; however, its precise mechanism of action has been hotly debated. In a recent paper in The Journal of Experimental Medicine [1] the Sharpe laboratory, who originally reported the phenotype of CTLA-4 null mice, brings us another intriguing installment in the CTLA-4 story. By generating mice with a floxed CTLA-4 allele, and crossing them to mice expressing a tamoxifen inducible Cre-recombinase, the authors constructed an experimental system in which CTLA-4 could be ablated 'at will' by tamoxifen administration. This permits for the first time the deletion of the CTLA-4 gene only in adult mice.
The first surprise in the data is that punctual ablation of the CTLA-4 gene in 7-week old mice failed to trigger spontaneous autoimmunity, contrasting with the situation following germline deletion. By contrast, deletion of CTLA-4 from the Treg compartment was sufficient to recapitulate the effects of systemic CTLA-4 deletion, with similar protection from EAE being observed. Thus in keeping with many other experimental settings, the major role of CTLA-4 was shown to be in Treg cells; however, unexpectedly this resulted in disease protection rather than disease exacerbation.
In keeping with previous work, the authors observed a dramatic expansion of the Treg cell population in CTLA-4-deleted mice, reflecting a marked increase in their proliferation ($60% Treg cells were Ki67 + in CTLA-4-deleted mice as compared to $30% in controls) [1] . This nicely parallels the increased Treg cell proliferation seen in mice lacking CTLA-4 from birth ($62% Treg were Ki67 + in CTLA-4 À/À mice compared with $28% in littermate controls) [2] . By ablating CTLA-4 specifically in the Treg compartment, using a tamoxifen-inducible cre under the control of the Foxp3 promoter, the authors were able to confirm that the Treg cell expansion was a direct effect of CTLA-4 in the of Ebi3, a subunit of the cytokine IL-27, which is known to inhibit Th17 differentiation and suppress EAE [6] . IL-27 is also recognized for its role in promoting the formation of type 1 regulatory T (Tr1) cells [6] , and it is notable that amounts of several typical Tr1 products are increased in the Tconv cells (e.g., IL-10, Ahr, ICOS, LAG3 [9] , and it is tempting to speculate that protection from autoimmunity in asymptomatic individuals results from compensatory mechanisms such as the overproduction of IL-10 reported here. Notably the autoimmune phenotype in symptomatic individuals with CTLA-4 heterozygosity manifests relatively late in life, contrasting with the early onset associated with Foxp3 deficiency in IPEX. It will be of great interest to track the status of CTLA-4-ablated mice during aging and following a variety of immunological challenges to gain a broader perspective on the role of CTLA-4 in different contexts. Meanwhile, the increasingly refined tools being used to unravel the biology of this critical immune regulator will doubtless continue to turn up new surprises.
